Conclusion
BRS offer an attractive theoretical advantage in absolution of late and very-late stent thrombosis. Despite promising clinical outcomes compared to existing DES, their use has been primarily restricted to patients recruited in clinical trials with strict eligibility criteria. Larger comparative trials with critical safety and efficacy analysis of newer BRS with improving designs and biomechanical properties are nearing completion. We eagerly await these results before the widespread use of BRS can be recommended, especially considering improving technology and outcomes with third generation metallic DES.